JP2021518431A5 - - Google Patents

Info

Publication number
JP2021518431A5
JP2021518431A5 JP2020573085A JP2020573085A JP2021518431A5 JP 2021518431 A5 JP2021518431 A5 JP 2021518431A5 JP 2020573085 A JP2020573085 A JP 2020573085A JP 2020573085 A JP2020573085 A JP 2020573085A JP 2021518431 A5 JP2021518431 A5 JP 2021518431A5
Authority
JP
Japan
Prior art keywords
constipation
dgat1
pharmaceutical composition
inhibitor
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020573085A
Other languages
English (en)
Japanese (ja)
Other versions
JP7527984B2 (ja
JP2021518431A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022499 external-priority patent/WO2019178492A1/en
Publication of JP2021518431A publication Critical patent/JP2021518431A/ja
Publication of JP2021518431A5 publication Critical patent/JP2021518431A5/ja
Application granted granted Critical
Publication of JP7527984B2 publication Critical patent/JP7527984B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020573085A 2018-03-16 2019-03-15 重度の便秘を治療するための組成物及び方法 Active JP7527984B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862644033P 2018-03-16 2018-03-16
US62/644,033 2018-03-16
PCT/US2019/022499 WO2019178492A1 (en) 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation

Publications (3)

Publication Number Publication Date
JP2021518431A JP2021518431A (ja) 2021-08-02
JP2021518431A5 true JP2021518431A5 (https=) 2022-02-21
JP7527984B2 JP7527984B2 (ja) 2024-08-05

Family

ID=67904819

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573085A Active JP7527984B2 (ja) 2018-03-16 2019-03-15 重度の便秘を治療するための組成物及び方法

Country Status (18)

Country Link
US (4) US11224590B2 (https=)
EP (1) EP3765012B1 (https=)
JP (1) JP7527984B2 (https=)
KR (1) KR102747096B1 (https=)
CN (1) CN111936137B (https=)
AU (1) AU2019234956B2 (https=)
BR (1) BR112020018790A2 (https=)
DK (1) DK3765012T3 (https=)
EA (1) EA202092190A1 (https=)
FI (1) FI3765012T3 (https=)
IL (1) IL277332B2 (https=)
MX (1) MX2020009604A (https=)
MY (1) MY205335A (https=)
PE (1) PE20210158A1 (https=)
PH (1) PH12020551468A1 (https=)
SG (1) SG11202008971VA (https=)
TW (1) TWI704917B (https=)
WO (1) WO2019178492A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092190A1 (ru) 2018-03-16 2020-11-19 Анджи Фармасьютикалз Инк. Композиции и способы для лечения сильного запора
KR20220052459A (ko) 2020-10-21 2022-04-28 주식회사 엘지에너지솔루션 전극 탭 고정부를 포함하는 용접장치 및 이를 이용한 전극 탭 용접 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3225997A (en) 1996-05-30 1998-01-05 Trustees Of Columbia University In The City Of New York, The Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
ATE406448T1 (de) 1998-06-24 2008-09-15 David Gladstone Inst Diacylglycerin o-acyltransferase
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
WO2002002551A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
RU2342388C2 (ru) 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
AU2005209115A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006004200A1 (ja) 2004-07-02 2006-01-12 Sankyo Company, Limited ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
WO2006044775A2 (en) 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
BRPI0519058A2 (pt) 2004-12-14 2008-12-23 Astrazeneca Ab composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
WO2006113919A2 (en) 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Aryl alkyl acid derivatives for and use thereof
WO2007002740A2 (en) 2005-06-28 2007-01-04 E. I. Du Pont De Nemours And Company Buffer compositions
EP2418202B1 (en) * 2006-03-31 2014-01-29 Novartis AG (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
NZ602125A (en) * 2010-03-30 2014-01-31 Novartis Ag Uses of dgat1 inhibitors
CN102869645A (zh) * 2010-04-08 2013-01-09 美迪诺亚公司 用于治疗肠易激综合征的方法和组合物
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013130370A2 (en) 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
MX2015002210A (es) * 2012-08-29 2015-05-08 Salix Pharmaceuticals Inc Composiciones laxantes y metodos para tratar estreñimiento y enfermedades y condiciones gastrointestinales relacionadas.
BR112016015851A2 (pt) * 2014-01-09 2017-08-08 Sanofi Sa Formulações farmacêuticas estabilizadas de insulina aspart
EA202092190A1 (ru) 2018-03-16 2020-11-19 Анджи Фармасьютикалз Инк. Композиции и способы для лечения сильного запора

Similar Documents

Publication Publication Date Title
Pandit et al. Current updates on oxazolidinone and its significance
JP5266430B2 (ja) 金属酵素阻害化合物
US20060106039A1 (en) Combinations
TW200412970A (en) Pharmaceutical composition comprising PDE 5 inhibitor and active ingredients
JP2007016035A5 (https=)
JP2017505293A5 (https=)
WO2000075113A1 (en) Novel heterocyclic carboxamide derivatives
JP7098214B2 (ja) 非アルコール性脂肪性肝炎（ＮＡＳＨ）の処置のためのｓＧＣ刺激物質の使用
JP2016516020A5 (https=)
TW200827344A (en) Administration of dipeptidyl peptidase inhibitors
JP2013521286A5 (https=)
JP2010519216A (ja) Ｃｃｒ５拮抗薬のための医薬組成物および方法
NZ594493A (en) Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors
JP2005517006A5 (https=)
JP2021518431A5 (https=)
JP2010516701A5 (https=)
ES2274234T3 (es) 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3(4-piridin-3-il)pirimidin -2-ilamino)fenil)-benzamida para el tratamiento de enfermedades mediadas por ang ii.
CA2605771A1 (en) Methods of treating atherosclerosis
US20070299047A1 (en) Combination of Organic Compounds
AU2006311723A1 (en) Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent
NZ590315A (en) Fxa inhibitors with cyclic amidoxime or cyclic amidrazone as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof
AU2007216580B2 (en) Sulfonamide derivatives for the treatment of bacterial infections
JP2012505225A5 (https=)
IL277332B1 (en) Compositions and methods for treating severe constipation
CN102143745A (zh) 用于治疗胃肠道的炎性病况的噁唑烷酮